Purple Biotech Ltd.
4 Oppenheimer Street, Science Park
Rehovot 7670104, Israel
November 13, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street N.E.
Washington, D.C. 20549
Attention: Jason Drory
| Re: | Purple Biotech Ltd. Filed October 30, 2023 File No. 333-275216 (the “Registration Statement”), as amended |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Purple Biotech Ltd. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement be accelerated by the Securities and Exchange Commission to 4:05 p.m., Eastern Time on November 14, 2023, or as soon thereafter as practicable.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to the Company’s counsel, Haynes and Boone, LLP, by calling Jayun Koo at (212) 835-4823, and that such effectiveness also be confirmed in writing.
Very truly yours,
Purple Biotech LTD. | ||
| By: | /s/ Gil Efron | |
| Gil Efron Chief Executive Officer | ||
| cc: | Rick A. Werner, Esq., Haynes and Boone, LLP |
| Jayun Koo, Esq., Haynes and Boone, LLP |